Interestingly, CAR T cells targeting tumor antigens have been modified to also constitutively secrete inhibitory checkpoint antibodies, such as anti-PDL-1 [69] or anti-PD-1 [70] mAbs, potentiating treatment efficacy. The gene discussed is CD274; the disease is neoplasm.